Roche Strikes Obesity Drug Licensing Deal Worth Up to $1.16 Billion
Roche entered a licensing agreement with Rona Therapeutics for its investigational obesity drug candidate, worth up to $1.16 billion, the Chinese biotech firm said Tuesday.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Roche strikes obesity drug licensing deal worth up to $1.16 bln with Chinese Rona Therapeutics
ZURICH, Oct 13 (Reuters) — Swiss drugmaker Roche entered a licensing agreement worth up to $1.16 billion with Rona Therapeutics for its investigational obesity drug candidate, the Chinese biotech firm said on Tuesday. Roche has been racing to break into the obesity drug market dominated by Eli Lilly and Novo Nordisk.